IRIDEX Corporation
1212 Terra Bella Avenue
Mountain View
California
94043
United States
Tel: 650-940-4700
Fax: 650-940-4710
Website: http://www.iridex.com/
Email: info@iridex.com
275 articles about IRIDEX Corporation
-
Iridex Corporation Receives European Patent on MicroPulse TechnologyThe Advanced Short Pulse Laser System
2/6/2024
Iridex Corporation (Nasdaq: IRIX) today announced the grant of the European Patent EP 3009093, entitled "Laser System with Short Pulse Characteristics and its Methods of Use”.
-
Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust
1/24/2024
Iridex Corporation today announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse ® Transscleral Laser Therapy (TLT) using Iridex’ Cyclo G6 ® Laser and the MicroPulse P3 ® Delivery Device.
-
Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation
12/28/2023
Iridex Corporation, a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, announced all five Medicare Administrative Contractors retired their local coverage determinations that were scheduled to take effect on January 29, 2024.
-
Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation
11/27/2023
Iridex Corporation announced its successful advocacy for revision of the recently issued Medicare Local Coverage Determinations for Cyclophotocoagulation.
-
Iridex Reports Third Quarter 2023 Financial Results and Business Update
11/14/2023
Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.
-
Iridex to Host Third Quarter Financial Results Conference Call on November 14, 2023
11/13/2023
Iridex Corporation announced the Company will host its third quarter financial results conference call on November 14, 2023 and plans to participate in the upcoming Stifel Healthcare Conference on November 15, 2023 in New York, NY.
-
Iridex to Report Third Quarter Financial Results on November 14, 2023
10/26/2023
Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2023 after the close of trading on Tuesday, November 14, 2023.
-
Iridex Announces Strategic Review to Unlock Shareholder Value
8/29/2023
Iridex Corporation announced that its Board of Directors is undertaking, in consultation with its financial and legal advisors, a review and evaluation of strategic alternatives that may be available to the Company to unlock shareholder value.
-
Iridex Reports Second Quarter 2023 Financial Results
8/10/2023
Iridex Corporation, a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, reported financial results for the second quarter ended July 1, 2023.
-
Iridex to Report Second Quarter Financial Results on August 10, 2023
7/27/2023
Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the second quarter of 2023 after the close of trading on Thursday, August 10, 2023.
-
Iridex Reports First Quarter 2023 Financial Results
5/11/2023
Iridex Corporation, a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, reported financial results for the first quarter ended April 1, 2023.
-
Iridex to Report First Quarter Financial Results on May 11, 2023
4/27/2023
Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter of 2023 after the close of trading on Thursday, May 11, 2023.
-
Iridex Reports Fourth Quarter and Full Year 2022 Financial Results
3/9/2023
Iridex Corporation reported financial results for the fourth quarter and year ended December 31, 2022 and issued 2023 financial guidance.
-
Iridex to Present at the 35th Annual Roth Conference
3/7/2023
Iridex Corporation today announced plans to participate in the upcoming 35th Annual Roth Conference in Laguna Niguel, CA.
-
Iridex Introduces New Research and Showcases Five Events at the AGS Meeting
3/2/2023
Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced Part 2 of the evidence-based guidelines series for MicroPulse Transscleral Laser Therapy (TLT) has been published in Clinical Ophthalmology1 by the international consensus panel of ten glaucoma experts.
-
Iridex to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023
2/23/2023
Iridex Corporation today announced the Company will release financial results for the fourth quarter and full year 2022 after the close of trading on Thursday, March 9, 2023.
-
Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2022
1/10/2023
Iridex Corporation today provided preliminary unaudited operational and financial results for the fourth quarter and full year ended December 31, 2022.
-
Iridex to Participate in Fireside Chat with Stifel Equity Research - December 06, 2022
12/6/2022
Iridex Corporation announced the Company plans to participate in a fireside chat with its covering equity research analyst from Stifel.
-
Iridex Announces Record Third Quarter 2022 Financial Results
11/10/2022
Iridex Corporation, a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, reported financial results for the third quarter ended October 1, 2022.
-
Iridex to Report Third Quarter 2022 Financial Results on November 10, 2022
10/27/2022
Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2022 after the close of trading on Thursday, November 10, 2022.